View in EDS

Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma.

Saved in:
Bibliographic Details
Title: Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma.
Authors: Dummer R; Department of Dermatology, Skin Cancer Unit, University Hospital Zurich, Zurich, Switzerland., Sandhu S; Sir Peter MacCallum Cancer Department of Oncology, University of Melbourne, Melbourne, Australia., Miller WH Jr; Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, Montreal, Canada.; Department of Medicine, McGill University, Montreal, Canada.; Department of Oncology, McGill University, Montreal, Canada., Butler MO; Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.; Department of Medicine, University of Toronto, Toronto, Canada.; Department of Immunology, University of Toronto, Toronto, Canada., Taylor MH; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon., Heinzerling L; Department of Dermatology and Allergy, University Hospital, Ludwig Maximilian University, Munich, Germany., Blank CU; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Muñoz-Couselo E; Department of Medical Oncology, Melanoma and Other Skin Cancers Unit, Vall d'Hebron Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Burris HA 3rd; Sarah Cannon Research Institute, Nashville, Tennessee., Postow MA; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York., Chmielowski B; Division of Hematology-Oncology, Department of Medicine, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California., Middleton MR; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, United Kingdom.; Department of Oncology, University of Oxford, Oxford, United Kingdom.; Early Phase Clinical Trials Unit, Cancer & Haematology Centre, Churchill Hospital, Oxford, United Kingdom., Berking C; Department of Dermatology, Uniklinikum Erlangen, CCC Erlangen - EMN, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany., Hassel JC; Department of Dermatology and National Center for Tumor Diseases (NCT), Heidelberg University, Medical Faculty Heidelberg, NCT Heidelberg, A Partnership Between DKFZ and University Hospital Heidelberg, Heidelberg, Germany., Gesierich AH; Department of Dermatology, Venerology and Allergology, University Hospital Würzburg, Würzburg, Germany., Mauch C; Department of Dermatology and Venereology, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany., Kleha JF; Pfizer, New York, New York., Polli A; Pfizer, Milan, Italy., Harney AS; Pfizer Boulder Research Unit, Boulder, Colorado., di Pietro A; Pfizer, Milan, Italy., Ascierto PA; Melanoma, Cancer Immunotherapy and Innovative Therapies Unit, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy.
Source: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2025 Jun 03; Vol. 31 (11), pp. 2097-2107.
Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study
Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40106536
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Dummer+R%22">Dummer R</searchLink>; Department of Dermatology, Skin Cancer Unit, University Hospital Zurich, Zurich, Switzerland.<br /><searchLink fieldCode="AU" term="%22Sandhu+S%22">Sandhu S</searchLink>; Sir Peter MacCallum Cancer Department of Oncology, University of Melbourne, Melbourne, Australia.<br /><searchLink fieldCode="AU" term="%22Miller+WH+Jr%22">Miller WH Jr</searchLink>; Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, Montreal, Canada.; Department of Medicine, McGill University, Montreal, Canada.; Department of Oncology, McGill University, Montreal, Canada.<br /><searchLink fieldCode="AU" term="%22Butler+MO%22">Butler MO</searchLink>; Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.; Department of Medicine, University of Toronto, Toronto, Canada.; Department of Immunology, University of Toronto, Toronto, Canada.<br /><searchLink fieldCode="AU" term="%22Taylor+MH%22">Taylor MH</searchLink>; Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, Oregon.<br /><searchLink fieldCode="AU" term="%22Heinzerling+L%22">Heinzerling L</searchLink>; Department of Dermatology and Allergy, University Hospital, Ludwig Maximilian University, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Blank+CU%22">Blank CU</searchLink>; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Muñoz-Couselo+E%22">Muñoz-Couselo E</searchLink>; Department of Medical Oncology, Melanoma and Other Skin Cancers Unit, Vall d'Hebron Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.<br /><searchLink fieldCode="AU" term="%22Burris+HA+3rd%22">Burris HA 3rd</searchLink>; Sarah Cannon Research Institute, Nashville, Tennessee.<br /><searchLink fieldCode="AU" term="%22Postow+MA%22">Postow MA</searchLink>; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York.<br /><searchLink fieldCode="AU" term="%22Chmielowski+B%22">Chmielowski B</searchLink>; Division of Hematology-Oncology, Department of Medicine, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, California.<br /><searchLink fieldCode="AU" term="%22Middleton+MR%22">Middleton MR</searchLink>; NIHR Oxford Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, United Kingdom.; Department of Oncology, University of Oxford, Oxford, United Kingdom.; Early Phase Clinical Trials Unit, Cancer & Haematology Centre, Churchill Hospital, Oxford, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Berking+C%22">Berking C</searchLink>; Department of Dermatology, Uniklinikum Erlangen, CCC Erlangen - EMN, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany.<br /><searchLink fieldCode="AU" term="%22Hassel+JC%22">Hassel JC</searchLink>; Department of Dermatology and National Center for Tumor Diseases (NCT), Heidelberg University, Medical Faculty Heidelberg, NCT Heidelberg, A Partnership Between DKFZ and University Hospital Heidelberg, Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Gesierich+AH%22">Gesierich AH</searchLink>; Department of Dermatology, Venerology and Allergology, University Hospital Würzburg, Würzburg, Germany.<br /><searchLink fieldCode="AU" term="%22Mauch+C%22">Mauch C</searchLink>; Department of Dermatology and Venereology, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.<br /><searchLink fieldCode="AU" term="%22Kleha+JF%22">Kleha JF</searchLink>; Pfizer, New York, New York.<br /><searchLink fieldCode="AU" term="%22Polli+A%22">Polli A</searchLink>; Pfizer, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Harney+AS%22">Harney AS</searchLink>; Pfizer Boulder Research Unit, Boulder, Colorado.<br /><searchLink fieldCode="AU" term="%22di+Pietro+A%22">di Pietro A</searchLink>; Pfizer, Milan, Italy.<br /><searchLink fieldCode="AU" term="%22Ascierto+PA%22">Ascierto PA</searchLink>; Melanoma, Cancer Immunotherapy and Innovative Therapies Unit, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229502500%22">Clinical cancer research : an official journal of the American Association for Cancer Research</searchLink> [Clin Cancer Res] 2025 Jun 03; Vol. 31 (11), pp. 2097-2107.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Association+for+Cancer+Research%22">American Association for Cancer Research </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>9502500 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1557-3265 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210780432%22">10780432 </searchLink><i>NLM ISO Abbreviation: </i>Clin Cancer Res <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40106536
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1158/1078-0432.CCR-24-0254
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2097
    Titles:
      – TitleFull: Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Dummer R
      – PersonEntity:
          Name:
            NameFull: Sandhu S
      – PersonEntity:
          Name:
            NameFull: Miller WH Jr
      – PersonEntity:
          Name:
            NameFull: Butler MO
      – PersonEntity:
          Name:
            NameFull: Taylor MH
      – PersonEntity:
          Name:
            NameFull: Heinzerling L
      – PersonEntity:
          Name:
            NameFull: Blank CU
      – PersonEntity:
          Name:
            NameFull: Muñoz-Couselo E
      – PersonEntity:
          Name:
            NameFull: Burris HA 3rd
      – PersonEntity:
          Name:
            NameFull: Postow MA
      – PersonEntity:
          Name:
            NameFull: Chmielowski B
      – PersonEntity:
          Name:
            NameFull: Middleton MR
      – PersonEntity:
          Name:
            NameFull: Berking C
      – PersonEntity:
          Name:
            NameFull: Hassel JC
      – PersonEntity:
          Name:
            NameFull: Gesierich AH
      – PersonEntity:
          Name:
            NameFull: Mauch C
      – PersonEntity:
          Name:
            NameFull: Kleha JF
      – PersonEntity:
          Name:
            NameFull: Polli A
      – PersonEntity:
          Name:
            NameFull: Harney AS
      – PersonEntity:
          Name:
            NameFull: di Pietro A
      – PersonEntity:
          Name:
            NameFull: Ascierto PA
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 03
              M: 06
              Text: 2025 Jun 03
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1557-3265
          Numbering:
            – Type: volume
              Value: 31
            – Type: issue
              Value: 11
          Titles:
            – TitleFull: Clinical cancer research : an official journal of the American Association for Cancer Research
              Type: main
ResultId 1